218 related articles for article (PubMed ID: 36058149)
1. Inhibition of α-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson's disease.
Kim S; Choi JG; Kim SW; Park SC; Kang YR; Park DS; Son M; Lee CH
Biomed Pharmacother; 2022 Oct; 154():113637. PubMed ID: 36058149
[TBL] [Abstract][Full Text] [Related]
2. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
[TBL] [Abstract][Full Text] [Related]
4. Cholecystokinin and glucagon-like peptide-1 analogues regulate intestinal tight junction, inflammation, dopaminergic neurons and α-synuclein accumulation in the colon of two Parkinson's disease mouse models.
Su Y; Liu N; Zhang Z; Li H; Ma J; Yuan Y; Shi M; Liu J; Zhao Z; Zhang Z; Holscher C
Eur J Pharmacol; 2022 Jul; 926():175029. PubMed ID: 35584709
[TBL] [Abstract][Full Text] [Related]
5. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
[TBL] [Abstract][Full Text] [Related]
6. Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS activation in transgenic Parkinson's disease models.
Zhu Q; Zhuang XX; Chen JY; Yuan NN; Chen Y; Cai CZ; Tan JQ; Su HX; Lu JH
Phytomedicine; 2021 Jul; 87():153578. PubMed ID: 34038839
[TBL] [Abstract][Full Text] [Related]
7. DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease.
Arkan S; Ljungberg M; Kirik D; Hansen C
Neurobiol Dis; 2021 Oct; 158():105477. PubMed ID: 34390836
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of green tea extract (-)-epigallocatechin-3-gallate in a preformed fibril-induced mouse model of Parkinson's disease.
Shen J; Xie J; Ye L; Mao J; Sun S; Chen W; Wei S; Ruan S; Wang L; Hu H; Wei J; Zheng Y; Xi Z; Wang K; Xu Y
Neuroreport; 2024 Apr; 35(6):421-430. PubMed ID: 38526966
[TBL] [Abstract][Full Text] [Related]
9. The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Lee S; Kim S; Park YJ; Yun SP; Kwon SH; Kim D; Kim DY; Shin JS; Cho DJ; Lee GY; Ju HS; Yun HJ; Park JH; Kim WR; Jung EA; Lee S; Ko HS
Hum Mol Genet; 2018 Jul; 27(13):2344-2356. PubMed ID: 29897434
[TBL] [Abstract][Full Text] [Related]
10. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
Benskey MJ; Perez RG; Manfredsson FP
J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
[TBL] [Abstract][Full Text] [Related]
11. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
12. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
13. REST Protects Dopaminergic Neurons from Mitochondrial and α-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model.
Ryan BJ; Bengoa-Vergniory N; Williamson M; Kirkiz E; Roberts R; Corda G; Sloan M; Saqlain S; Cherubini M; Poppinga J; Bogtofte H; Cioroch M; Hester S; Wade-Martins R
J Neurosci; 2021 Apr; 41(16):3731-3746. PubMed ID: 33563726
[TBL] [Abstract][Full Text] [Related]
14. Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson's disease.
Yang J; Luo S; Zhang J; Yu T; Fu Z; Zheng Y; Xu X; Liu C; Fan M; Zhang Z
Neurobiol Dis; 2021 Jan; 148():105218. PubMed ID: 33296726
[TBL] [Abstract][Full Text] [Related]
15. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
16. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
[TBL] [Abstract][Full Text] [Related]
17. Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment.
Que R; Zheng J; Chang Z; Zhang W; Li H; Xie Z; Huang Z; Wang HT; Xu J; Jin D; Yang W; Tan EK; Wang Q
Front Immunol; 2021; 12():794770. PubMed ID: 34925379
[TBL] [Abstract][Full Text] [Related]
18. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
19. The SUMO Conjugase Ubc9 Protects Dopaminergic Cells from Cytotoxicity and Enhances the Stability of α-Synuclein in Parkinson's Disease Models.
Verma DK; Ghosh A; Ruggiero L; Cartier E; Janezic E; Williams D; Jung EG; Moore M; Seo JB; Kim YH
eNeuro; 2020; 7(5):. PubMed ID: 32887693
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Peucedanocoumarin IV Prevents α-Synuclein Neurotoxicity in an Animal Model of Parkinson's Disease.
Kim H; Maeng HJ; Kim JH; Yoon JH; Oh Y; Paek SM; Lee Y
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
